Cantor Fitzgerald Cuts Earnings Estimates for Biohaven

Biohaven Ltd. (NYSE:BHVN - Free Report) - Investment analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Biohaven in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings of ($6.80) per share for the year, down from their prior forecast of ($6.05). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share.

A number of other equities research analysts have also recently issued reports on the stock. TD Cowen upped their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. Morgan Stanley reduced their target price on Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft started coverage on shares of Biohaven in a report on Tuesday, February 11th. They set a "buy" rating and a $65.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Biohaven currently has an average rating of "Buy" and an average target price of $63.15.

Remove Ads

Biohaven Price Performance

Biohaven stock traded down $2.40 during midday trading on Thursday, reaching $27.47. The stock had a trading volume of 1,903,726 shares, compared to its average volume of 995,616. Biohaven has a twelve month low of $26.80 and a twelve month high of $60.83. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of -2.94 and a beta of 1.27. The firm's fifty day simple moving average is $37.72 and its two-hundred day simple moving average is $42.45.

Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29).

Hedge Funds Weigh In On Biohaven

Several large investors have recently added to or reduced their stakes in BHVN. HighTower Advisors LLC raised its position in Biohaven by 6.1% in the 4th quarter. HighTower Advisors LLC now owns 5,870 shares of the company's stock valued at $219,000 after buying an additional 335 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Biohaven by 0.5% during the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company's stock worth $4,206,000 after acquiring an additional 412 shares during the period. KBC Group NV increased its stake in shares of Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company's stock worth $112,000 after purchasing an additional 443 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in Biohaven by 19.1% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company's stock worth $156,000 after buying an additional 500 shares during the period. Finally, FSC Wealth Advisors LLC grew its stake in Biohaven by 3.3% in the 4th quarter. FSC Wealth Advisors LLC now owns 15,500 shares of the company's stock valued at $579,000 after buying an additional 500 shares in the last quarter. Institutional investors own 88.78% of the company's stock.

Insider Activity at Biohaven

In other Biohaven news, Director John W. Childs acquired 29,000 shares of the stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the acquisition, the director now owns 2,368,741 shares in the company, valued at approximately $85,132,551.54. This represents a 1.24 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by company insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.